DRG Market Assessment 보고서

The treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has enormous potential for growth owing to the disease’s…

The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical…

Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently…

Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that results in progressive loss of vision. In contrast to many other forms of macular…

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients…

Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…

The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…